{"gene":"TNFRSF1A","run_date":"2026-06-10T10:51:55","timeline":{"discoveries":[{"year":1998,"finding":"TNFRSF1A (TNF-R1/CD120a/TNFR60) is the high-affinity receptor for soluble TNF, with a Kd of ~19 pM at 37°C, approximately 20-fold higher affinity than TNFR2 (Kd ~420 pM). The high affinity is primarily due to the marked stability of the TNF–TNFR1 complex, explaining the predominant role of TNFR1 in cellular responses to soluble TNF.","method":"Binding kinetics (association and dissociation rate constants) measured at 37°C for both TNF receptors","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct in vitro binding assay with quantitative kinetic measurements, mechanistically explains receptor selectivity","pmids":["9435233"],"is_preprint":false},{"year":1990,"finding":"The extracellular domain of TNFRSF1A contains four cysteine-rich repeats homologous to NGF receptor and CDw40. The receptor lacks intrinsic protein kinase activity yet can signal phosphorylation of specific cellular proteins. Soluble forms of the receptor are structurally identical to the extracellular cytokine-binding domain and are derived from the same transcripts encoding the cell-surface receptor.","method":"cDNA cloning using NH2-terminal amino acid sequence of soluble TBPI; transfection of CHO cells; immunological characterization with monoclonal antibodies","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — cDNA cloning with functional validation, amino acid sequence analysis, transfection experiments; foundational structural characterization","pmids":["1698610"],"is_preprint":false},{"year":1994,"finding":"TNF binding to TNFRSF1A (TNFR60/CD120a) induces rapid, ligand-concentration-dependent association of a serine protein kinase activity with TNFR60 immune complexes, along with several phosphoproteins. The TNFR60-associated kinase activity phosphorylates proteins of 125, 97, 85, and 60 kDa and is inhibited by staurosporine but not by PKA/PKC inhibitors. TNFR80 did not show similar kinase association.","method":"Immunoprecipitation of TNFR60 from 32P-labeled U-937 cells; in vitro kinase assay on immune complexes; pharmacological inhibition","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal immunoprecipitation with in vitro kinase assay, single lab, well-controlled","pmids":["8089485"],"is_preprint":false},{"year":1995,"finding":"Cross-linking of TNFRSF1A (CD120a/p55) alone, but not CD120b (p75), is both necessary and sufficient for activation of p42mapk/erk2 in mouse macrophages, as determined using blocking and agonistic receptor-specific antibodies.","method":"Specific agonistic and blocking antibodies against each TNF receptor; p42mapk/erk2 activation measured by tyrosine phosphorylation in mouse macrophages","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — receptor-specific antibody approach with both blocking and agonistic reagents, single lab","pmids":["7636214"],"is_preprint":false},{"year":1998,"finding":"FADD (dominant-negative mutant) is part of the TNFR60-initiated apoptotic pathway but does not play a role in TNFR60-mediated NF-κB or JNK gene induction. GFP-ΔFadd expression in HeLa cells inhibited TNFR60-, Fas/Apo1- and TRAIL-R/Apo2-mediated cell death without affecting TNF-mediated NF-κB or JNK activation.","method":"Stable expression of GFP-tagged dominant-negative FADD in HeLa cells; NF-κB and JNK activation assays; apoptosis assays","journal":"Current biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — dominant-negative genetic approach with multiple signaling readouts, dissecting apoptotic from gene-inductive signaling downstream of TNFR60","pmids":["9427646"],"is_preprint":false},{"year":1998,"finding":"TNFR-associated factor 2 (TRAF2) is critically involved in both negative and positive regulation of TNFR60-induced cell death. TNFR80 costimulation enhances TNFR60-induced cell death selectively (not Fas/TRAIL/ceramide/daunorubicin-mediated death) through TNFR80-mediated depletion of antiapoptotic TRAF2 function. Overexpression of TRAF2 desensitized TNFR60-induced cell death, while a TRAF2 NF-κB-activation-deficient mutant enhanced it.","method":"Overexpression of wild-type and mutant TRAF2 in HeLa cells; receptor-specific antibody costimulation; JNK activation assays; cell death assays","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple mutant constructs with orthogonal functional readouts (cell death, JNK activation, NF-κB), mechanistic epistasis established","pmids":["9743381"],"is_preprint":false},{"year":1998,"finding":"Cross-linking of TNFRSF1A (CD120a/p55) is necessary and sufficient to induce iNOS mRNA expression and NO2- production in mouse macrophages, while CD120b (p75) augments this response by ligand-passing to CD120a and by initiating a separate sustained signaling event. Simultaneous ligation of both receptors leads to markedly prolonged iNOS mRNA/protein expression and potentiated nitric oxide production.","method":"Receptor-specific antibody-mediated cross-linking; anti-receptor blocking antibodies; CD120a- and CD120b-deficient mice; iNOS mRNA, protein, and NO2- quantification","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — receptor-specific antibodies, knockout mice, and multiple molecular readouts in a single study","pmids":["9712914"],"is_preprint":false},{"year":1999,"finding":"p42mapk/erk2 phosphorylates the cytoplasmic domain of TNFRSF1A (CD120a/p55) at multiple Ser/Thr residues. Phosphorylation was induced by TNFα, GM-CSF, M-CSF, and zymosan in macrophages and blocked by immunodepletion of p42mapk/erk2 or PD098059. As a consequence of phosphorylation, CD120a expression at the plasma membrane and Golgi apparatus is lost and the receptor accumulates in intracellular tubular structures associated with the endoplasmic reticulum. Mutation of the four ERK consensus phosphorylation sites to Ala prevented ER-tubular redistribution.","method":"GST-CD120a fusion protein as substrate for in vitro phosphorylation; 32P metabolic labeling; COS-7 cell transfection with CD120a and constitutively active MEK-1; site-directed mutagenesis; confocal microscopy","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro kinase assay, metabolic labeling, site-directed mutagenesis, and subcellular localization, multiple orthogonal methods","pmids":["10551865"],"is_preprint":false},{"year":2000,"finding":"The preferred phosphorylation sites on TNFRSF1A (CD120a/p55) by p42mapk/erk2 are Thr-236 and Ser-270 within the membrane proximal region; primary phosphorylation at these sites enables subsequent phosphorylation at Ser-240 and Ser-244. CD120a (p55) itself is necessary and sufficient for induction of ERK kinase activity, as demonstrated using receptor-deficient mice.","method":"Deletional and site-directed mutagenesis of CD120a cytoplasmic domain; 32P phosphorylation mapping; mice deficient in CD120a, CD120b, or both","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — site-directed mutagenesis plus genetic knockout mice, identifying specific phosphorylation sites","pmids":["10702263"],"is_preprint":false},{"year":2001,"finding":"Phosphorylation of TNFRSF1A (CD120a) by p42mapk/erk2 inhibits the apoptotic activity of the receptor while preserving its ability to activate NF-κB. Phosphorylated CD120a is re-localized from the Golgi to tubular ER structures where it recruits Bcl-2. Antisense-mediated knockdown of Bcl-2 reversed the protection from apoptosis conferred by receptor phosphorylation.","method":"p42mapk/erk2 overexpression; antisense Bcl-2 knockdown; subcellular localization; apoptosis and NF-κB assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal approaches (kinase overexpression, antisense knockdown, localization, functional apoptosis/NF-κB assays) in single study","pmids":["11278725"],"is_preprint":false},{"year":2002,"finding":"The death domain (DD) of TNFRSF1A (CD120a) is both necessary and sufficient to promote localization of the receptor to lipid rafts. Deletion of the DD, pairwise deletion of individual DD alpha-helices, or introduction of the lpr mutation (L351N) all prevented raft localization and abolished apoptotic signaling. CD120b (which lacks a DD) is absent from the Golgi but present in bulk plasma membrane; a chimeric receptor with the CD120a DD fused to CD120b cytoplasmic domain was predominantly localized to lipid rafts.","method":"Confocal microscopy; sucrose density gradient ultracentrifugation; deletion and point mutagenesis; chimeric receptor construction; apoptosis assays","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1 / Strong — mutagenesis combined with fractionation and imaging, directly linking DD-mediated raft localization to apoptotic signaling","pmids":["11937569"],"is_preprint":false},{"year":2000,"finding":"One mechanism of autoinflammation in TRAPS is impaired cleavage/shedding of the TNFRSF1A ectodomain upon cellular activation in patients with certain mutations. Mutations in the extracellular cysteine-rich domains (especially those disrupting disulfide bonds) reduce shedding of the soluble antagonistic form of the receptor.","method":"Functional studies of TNFRSF1A shedding in patient cells; mutational analysis of extracellular domain","journal":"Current opinion in immunology","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — functional shedding assays in patient-derived cells, replicated across multiple TRAPS patient studies","pmids":["10899034"],"is_preprint":false},{"year":2007,"finding":"A novel splice-site mutation in TNFRSF1A (c.472+1G>A) causes a 45-nucleotide insertion of intronic DNA resulting in an in-frame insertion of 15 amino acids and deletion of Cys129 in CRD3 of the mature TNFR1 protein. This mutation reduces serum soluble TNFR1 levels, decreases surface TNFR1 expression, and increases basal NF-κB activation in PBMCs compared with healthy controls and other TRAPS mutations.","method":"Western blot; multiplex bead cytokine immunoassay; ELISA for sTNFR1; FACS for surface TNFR1; NF-κB ELISA-based transcription factor assay","journal":"Annals of the rheumatic diseases","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (protein expression, surface expression, signaling), single lab patient study","pmids":["18086728"],"is_preprint":false},{"year":2015,"finding":"The novel S59P TNFRSF1A mutation causes cytoplasmic accumulation/defective trafficking of TNF-R1 and constitutively activates the NF-κB, IL-1β, MAPK, and SRC/JAK/STAT3 pathways and inhibits apoptosis. This mutation also leads to enhanced and persistent IL-6 and IL-8 secretion from PBMCs in response to IL-1β stimulation.","method":"HEK-293 cell transfection with mutant constructs; immunofluorescence; immunoblotting for p-IκBα and p65; cytokine array; PBMC stimulation assays","journal":"Arthritis research & therapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — transfection-based functional study with multiple signaling readouts and patient PBMC validation, single lab","pmids":["25888769"],"is_preprint":false},{"year":2013,"finding":"The MS susceptibility allele rs1800693(G) in the TNFRSF1A locus generates an RNA isoform, TNFRSF1A Δ6, lacking the transmembrane and cytoplasmic domains. This allele alters monocyte responses, causing a more robust transcriptional induction of CXCL10 and other genes in response to TNF-α, without detectably altering serum levels of soluble TNFRSF1A.","method":"Real-time PCR for isoform expression; ELISA for serum sTNFR1; transcriptional profiling of monocytes from genotyped donors; prospective clinical data analysis","journal":"Neurology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — isoform characterization and functional monocyte assays, single lab but multiple methods","pmids":["24174586"],"is_preprint":false},{"year":2018,"finding":"TNFRSF1A is a direct transcriptional target of STAT3 in breast cancer cells. STAT3 binds directly to a regulatory region within the TNFRSF1A gene, and TNFRSF1A levels depend on STAT3 function in both constitutive and cytokine-induced STAT3 activation models. TNFRSF1A is a major mediator of both basal and TNFα-induced NF-κB activity in triple-negative breast cancer cells.","method":"STAT3 inhibitor treatment + gene expression analysis; chromatin binding assay (STAT3 binding to TNFRSF1A regulatory region); siRNA knockdown of TNFRSF1A; NF-κB reporter assays","journal":"Neoplasia","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct STAT3 binding to TNFRSF1A regulatory region plus functional knockdown with NF-κB readout, single lab, two orthogonal methods","pmids":["29621649"],"is_preprint":false},{"year":2018,"finding":"In TRAPS patient-derived dermal fibroblasts carrying TNFRSF1A mutations, TNFR1 surface expression is absent/deficient. These cells fail to upregulate miR-146a and miR-155 in response to LPS, leading to hyperresponsive cytokine production. This failure is mechanistically dependent on IRE1 (inositol-requiring enzyme 1): IL-1β produced by unfolded protein response activation downregulates miR-146a and miR-155 in an IRE1-dependent manner, impairing NF-κB negative feedback.","method":"Immunofluorescence for TNFR1 surface expression; RT-qPCR for miRNA expression; IRE1 inhibitor (4u8C); ELISA for cytokines; microfluidics miRNA profiling","journal":"Frontiers in immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — patient-derived fibroblasts with pharmacological inhibitor and multiple readouts, single lab","pmids":["29467762"],"is_preprint":false},{"year":2006,"finding":"Neutrophils from TRAPS patients with cysteine or threonine residue mutations (but not those with the R92Q substitution) display resistance to TNF-induced apoptosis and absent caspase-8 activation, in contrast to normal controls and R92Q carriers, suggesting that structural TNFRSF1A mutations impair TNFR1-mediated apoptotic signaling.","method":"Neutrophil stimulation with TNFα + cycloheximide; annexin V binding by flow cytometry; caspase-8 activation assay","journal":"Arthritis and rheumatism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional apoptosis and caspase assays in patient-derived primary cells, multiple mutation types compared, single lab","pmids":["16508982"],"is_preprint":false},{"year":1997,"finding":"In HIV-infected T cells, TNFR60 (TNFRSF1A) dominantly signals HIV production upon selective stimulation, while simultaneous activation of both TNFR60 and TNFR80 by membrane TNF (but not soluble TNF) switches the cellular response from viral production to enhanced apoptosis, demonstrating cooperative/antagonistic signaling between the two TNF receptors.","method":"Receptor-specific agonistic and antagonistic antibodies; coculture with cells expressing noncleavable membrane TNF; HIV production measurement; apoptosis assays","journal":"The Journal of experimental medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — receptor-specific antibodies and membrane-TNF coculture system with functional readouts, single lab","pmids":["8996244"],"is_preprint":false},{"year":2015,"finding":"High-penetrance TNFRSF1A mutations cause hyperactivation of ERK1/2, STAT1/3/5, mTOR, and NF-κB signaling pathways in conventional CD4+ T cells, and reduce the frequency and suppressive function of peripheral regulatory T cells. Low-penetrance mutations show partial versions of these alterations.","method":"Phosphoflow cytometry for signaling pathways; frequency and functional assays of Treg and conventional T cells in TRAPS patient peripheral blood","journal":"Journal of leukocyte biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — patient-derived primary cells with multiple signaling readouts, single lab","pmids":["26598380"],"is_preprint":false}],"current_model":"TNFRSF1A (TNFR1/CD120a/p55) is the high-affinity, death domain-containing receptor for soluble TNF that, upon ligand binding and clustering, recruits FADD and TRAF2 to activate both NF-κB (gene induction) and caspase-dependent apoptosis; its death domain is required for lipid raft localization and apoptotic signaling, while phosphorylation of its cytoplasmic domain by p42mapk/erk2 at Thr-236/Ser-270 redistributes the receptor to ER tubules where it recruits Bcl-2 to suppress apoptosis while preserving NF-κB signaling; soluble TNFRSF1A generated by ectodomain shedding acts as an antagonist, and disease-causing TRAPS mutations in the extracellular cysteine-rich domains impair shedding and receptor trafficking, leading to constitutive NF-κB and inflammasome pathway activation; additionally, TNFRSF1A is a direct STAT3 transcriptional target that mediates basal and TNFα-induced NF-κB activity in cancer cells."},"narrative":{"mechanistic_narrative":"TNFRSF1A (TNFR1/CD120a/p55) is the high-affinity receptor for soluble TNF, binding with ~19 pM affinity owing to the marked stability of the TNF–TNFR1 complex, which explains its predominant role in cellular responses to soluble TNF relative to TNFR2 [PMID:9435233]. Its extracellular region comprises four cysteine-rich repeats and, although the receptor lacks intrinsic kinase activity, ligand binding drives signaling through recruited effectors [PMID:1698610]. Upon engagement, TNFR1 bifurcates into a death-inducing pathway dependent on FADD and a gene-inductive NF-κB/JNK pathway that proceeds independently of FADD [PMID:9427646], with TRAF2 acting as a rheostat that both restrains and licenses TNFR1-induced cell death [PMID:9743381]; cross-linking of TNFR1 alone is necessary and sufficient to activate p42mapk/erk2 and to induce iNOS expression in macrophages [PMID:7636214, PMID:9712914]. The receptor's death domain is both necessary and sufficient for partitioning into lipid rafts, a localization required for apoptotic signaling [PMID:11937569]. TNFR1 signaling output is tuned by ERK-dependent phosphorylation: p42mapk/erk2 phosphorylates the cytoplasmic domain at Thr-236 and Ser-270 (priming further phosphorylation at Ser-240/Ser-244), redistributing the receptor from the Golgi/plasma membrane into ER-associated tubular structures where it recruits Bcl-2 to suppress apoptosis while preserving NF-κB activation [PMID:10551865, PMID:10702263, PMID:11278725]. Mutations in the extracellular cysteine-rich domains cause TNF receptor-associated periodic syndrome (TRAPS) by impairing ectodomain shedding and receptor trafficking, producing surface-deficient, cytoplasmically retained receptor that constitutively drives NF-κB, IL-1β/MAPK, and STAT3 signaling, resists TNF-induced apoptosis, and disrupts NF-κB negative feedback [PMID:10899034, PMID:25888769, PMID:29467762, PMID:16508982]. TNFRSF1A is itself a direct STAT3 transcriptional target that mediates basal and TNFα-induced NF-κB activity in breast cancer cells [PMID:29621649].","teleology":[{"year":1990,"claim":"Established the molecular identity of TNFR1 as a four-cysteine-rich-repeat surface receptor lacking intrinsic kinase activity, defining how it must signal through recruited partners and explaining the origin of soluble receptor.","evidence":"cDNA cloning from soluble TBPI sequence, CHO transfection, and monoclonal antibody characterization","pmids":["1698610"],"confidence":"High","gaps":["Did not identify the kinases or adaptors that mediate phosphorylation downstream","Mechanism of soluble receptor generation not resolved"]},{"year":1994,"claim":"Showed that TNF binding selectively recruits a serine kinase activity to TNFR1 (not TNFR2), beginning to explain how a kinase-deficient receptor transduces phosphorylation signals.","evidence":"Immunoprecipitation of TNFR60 from 32P-labeled U-937 cells with in vitro kinase assay and pharmacological inhibition","pmids":["8089485"],"confidence":"Medium","gaps":["Identity of the associated kinase not established","Substrate proteins (125/97/85/60 kDa) not identified"]},{"year":1995,"claim":"Demonstrated that TNFR1 cross-linking alone is necessary and sufficient to activate ERK2, attributing a specific MAPK output to this receptor.","evidence":"Receptor-specific agonistic/blocking antibodies and ERK2 tyrosine phosphorylation readout in mouse macrophages","pmids":["7636214"],"confidence":"Medium","gaps":["Did not map the route from receptor to ERK activation","Single cell type"]},{"year":1997,"claim":"Revealed receptor cross-talk: TNFR1 dominantly signals HIV production, but co-activation with TNFR2 by membrane TNF switches output toward apoptosis, showing ligand form dictates outcome.","evidence":"Receptor-specific antibodies and noncleavable membrane-TNF coculture in HIV-infected T cells","pmids":["8996244"],"confidence":"Medium","gaps":["Molecular basis of the soluble-vs-membrane TNF switch not defined","Single-lab system"]},{"year":1998,"claim":"Separated TNFR1's two signaling arms genetically — FADD drives apoptosis but is dispensable for NF-κB/JNK — and identified TRAF2 as a bidirectional regulator of death, establishing the apoptosis-versus-gene-induction dichotomy.","evidence":"Dominant-negative FADD and wild-type/mutant TRAF2 overexpression in HeLa with cell death, NF-κB, and JNK readouts","pmids":["9427646","9743381"],"confidence":"High","gaps":["Structural basis of FADD vs TRAF2 recruitment not resolved","How TRAF2 levels are set in vivo unclear"]},{"year":1998,"claim":"Quantified TNFR1 as the high-affinity soluble-TNF receptor and attributed selectivity to complex stability, explaining why TNFR1 dominates responses to soluble ligand.","evidence":"Binding kinetics with association/dissociation rate constants at 37°C for both receptors","pmids":["9435233"],"confidence":"High","gaps":["Does not address membrane-TNF binding behavior","No structural model of the stabilized complex"]},{"year":1998,"claim":"Showed TNFR1 is necessary and sufficient to induce iNOS/NO in macrophages with TNFR2 augmenting via ligand-passing, mapping an inflammatory effector output to the receptor.","evidence":"Receptor-specific antibodies, knockout mice, and iNOS mRNA/protein/NO2- quantification","pmids":["9712914"],"confidence":"High","gaps":["Intracellular pathway linking TNFR1 to iNOS not fully traced"]},{"year":1999,"claim":"Identified ERK2 as the kinase phosphorylating the TNFR1 cytoplasmic domain at multiple Ser/Thr sites, with phosphorylation driving relocation from plasma membrane/Golgi into ER tubules — linking covalent modification to receptor trafficking.","evidence":"GST-CD120a in vitro kinase assay, 32P labeling, site-directed mutagenesis, and confocal microscopy in COS-7 cells","pmids":["10551865"],"confidence":"High","gaps":["Functional consequence of ER relocation not yet shown","Sequence/identity of phospho-sites not yet mapped at this stage"]},{"year":2000,"claim":"Pinpointed Thr-236 and Ser-270 as primary ERK phosphorylation sites priming secondary Ser-240/Ser-244 phosphorylation, providing residue-level resolution of the trafficking switch.","evidence":"Deletional/site-directed mutagenesis, 32P phospho-mapping, and TNF-receptor-deficient mice","pmids":["10702263"],"confidence":"High","gaps":["The phosphatase reversing these modifications unknown","Stoichiometry of phosphorylation in vivo unclear"]},{"year":2001,"claim":"Established the functional output of ERK phosphorylation: relocated TNFR1 recruits Bcl-2 in ER tubules to block apoptosis while preserving NF-κB, defining a phosphorylation-controlled pro-survival switch.","evidence":"ERK2 overexpression, antisense Bcl-2 knockdown, localization, and apoptosis/NF-κB assays","pmids":["11278725"],"confidence":"High","gaps":["Direct TNFR1–Bcl-2 interaction interface not defined","Generality across cell types not established"]},{"year":2002,"claim":"Showed the death domain is necessary and sufficient for TNFR1 lipid-raft localization and that raft partitioning is required for apoptosis, tying a specific subdomain to a specific signaling compartment.","evidence":"Deletion/point mutagenesis (including lpr L351N), chimeric receptors, sucrose-gradient fractionation, confocal imaging, and apoptosis assays","pmids":["11937569"],"confidence":"High","gaps":["Raft components recruited by the DD not identified","Relationship between raft and ER-tubule pools unresolved"]},{"year":2006,"claim":"Demonstrated that structural (cysteine/threonine) TRAPS mutations, but not R92Q, impair TNFR1-mediated apoptosis with absent caspase-8 activation, linking specific mutation classes to defective death signaling.","evidence":"TNFα+cycloheximide stimulation of patient neutrophils with annexin V and caspase-8 assays","pmids":["16508982"],"confidence":"Medium","gaps":["Mechanism connecting structural mutation to caspase-8 failure not defined","Small mutation-type cohort"]},{"year":2000,"claim":"Proposed impaired ectodomain shedding as a TRAPS mechanism, where CRD mutations reduce production of the antagonistic soluble receptor.","evidence":"Functional shedding assays in patient cells with extracellular-domain mutational analysis","pmids":["10899034"],"confidence":"Medium","gaps":["Shedding defect does not explain all TRAPS mutations","Quantitative contribution to disease unclear"]},{"year":2007,"claim":"Linked a specific splice/CRD3 mutation to reduced soluble and surface TNFR1 with elevated basal NF-κB, refining the trafficking-defect model of TRAPS.","evidence":"Western blot, sTNFR1 ELISA, surface FACS, and NF-κB transcription-factor assay in patient PBMCs","pmids":["18086728"],"confidence":"Medium","gaps":["Mechanism connecting retention to constitutive NF-κB not established","Single mutation"]},{"year":2013,"claim":"Showed the MS-associated rs1800693(G) allele produces a soluble TNFRSF1A Δ6 isoform lacking transmembrane/cytoplasmic domains and enhances TNF-driven CXCL10 induction in monocytes, connecting a common variant to altered TNF responsiveness.","evidence":"Isoform RT-PCR, serum sTNFR1 ELISA, and monocyte transcriptional profiling in genotyped donors","pmids":["24174586"],"confidence":"Medium","gaps":["How the Δ6 isoform alters signaling mechanistically unclear","No change in serum soluble receptor detected"]},{"year":2015,"claim":"Demonstrated that an S59P TRAPS mutation causes cytoplasmic receptor retention and constitutive activation of NF-κB, IL-1β, MAPK, and SRC/JAK/STAT3 pathways with apoptosis resistance, broadening the multi-pathway hyperactivation model.","evidence":"HEK-293 transfection, immunofluorescence, immunoblotting, cytokine arrays, and patient PBMC stimulation","pmids":["25888769"],"confidence":"Medium","gaps":["Mechanism converting trafficking defect to constitutive multi-pathway activation undefined","Single mutation"]},{"year":2015,"claim":"Extended TRAPS signaling dysregulation to adaptive immunity, showing high-penetrance mutations hyperactivate ERK/STAT/mTOR/NF-κB in CD4+ T cells and impair regulatory T cells.","evidence":"Phosphoflow cytometry and Treg frequency/function assays in patient peripheral blood","pmids":["26598380"],"confidence":"Medium","gaps":["Cell-intrinsic vs systemic causes of Treg defect not separated","Penetrance-dependent mechanism not resolved"]},{"year":2018,"claim":"Connected TRAPS receptor deficiency to failed miRNA-based NF-κB feedback via an IRE1/UPR–IL-1β axis, providing a mechanistic basis for cytokine hyperresponsiveness.","evidence":"Patient-derived fibroblasts, RT-qPCR for miR-146a/miR-155, IRE1 inhibitor 4u8C, and cytokine ELISA","pmids":["29467762"],"confidence":"Medium","gaps":["How TNFR1 deficiency triggers UPR not defined","In vivo relevance to flares unclear"]},{"year":2018,"claim":"Identified TNFRSF1A as a direct STAT3 transcriptional target driving basal and TNFα-induced NF-κB in triple-negative breast cancer, placing the receptor downstream of an oncogenic transcription factor.","evidence":"STAT3 inhibition with expression analysis, STAT3 chromatin-binding assay, TNFRSF1A siRNA, and NF-κB reporter assays","pmids":["29621649"],"confidence":"Medium","gaps":["STAT3-binding element not finely mapped","In vivo tumor relevance not tested"]},{"year":null,"claim":"How the lipid-raft (death-inducing) and ER-tubule (Bcl-2-protective) receptor pools are dynamically partitioned, and how this balance is dysregulated by TRAPS mutations to drive constitutive inflammation, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking phospho-trafficking, raft localization, and TRAPS pathology","Phosphatases and shedding proteases not characterized in the corpus"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,1,4]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[9,10]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[7,10]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[7,9]},{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[7,10]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,4,5]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[4,9,10,17]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[6,16,19]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[11,13,16]}],"complexes":[],"partners":["TNF","FADD","TRAF2","BCL2","STAT3"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P19438","full_name":"Tumor necrosis factor receptor superfamily member 1A","aliases":["Tumor necrosis factor receptor 1","TNF-R1","Tumor necrosis factor receptor type I","TNF-RI","TNFR-I","p55","p60"],"length_aa":455,"mass_kda":50.5,"function":"Receptor for TNFSF2/TNF and homotrimeric TNFSF1/lymphotoxin-alpha. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Contributes to the induction of non-cytocidal TNF effects including anti-viral state and activation of the acid sphingomyelinase","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P19438/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TNFRSF1A","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TNFRSF1A","total_profiled":1310},"omim":[{"mim_id":"620293","title":"TMEM9 DOMAIN FAMILY, MEMBER B; TMEM9B","url":"https://www.omim.org/entry/620293"},{"mim_id":"617464","title":"UNC5 FAMILY C-TERMINAL-LIKE PROTEIN; UNC5CL","url":"https://www.omim.org/entry/617464"},{"mim_id":"617321","title":"YAO SYNDROME; YAOS","url":"https://www.omim.org/entry/617321"},{"mim_id":"616567","title":"DEATH-ASSOCIATED PROTEIN KINASE 2; DAPK2","url":"https://www.omim.org/entry/616567"},{"mim_id":"614810","title":"MULTIPLE SCLEROSIS, SUSCEPTIBILITY TO, 5; MS5","url":"https://www.omim.org/entry/614810"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/TNFRSF1A"},"hgnc":{"alias_symbol":["TNF-R","TNFAR","TNFR60","TNF-R-I","CD120a","TNF-R55"],"prev_symbol":["TNFR1"]},"alphafold":{"accession":"P19438","domains":[{"cath_id":"2.10.50.10","chopping":"43-124","consensus_level":"medium","plddt":96.325,"start":43,"end":124},{"cath_id":"2.10.50.10","chopping":"128-196","consensus_level":"high","plddt":91.1023,"start":128,"end":196},{"cath_id":"1.10.533.10","chopping":"357-443","consensus_level":"high","plddt":84.8103,"start":357,"end":443}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P19438","model_url":"https://alphafold.ebi.ac.uk/files/AF-P19438-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P19438-F1-predicted_aligned_error_v6.png","plddt_mean":71.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TNFRSF1A","jax_strain_url":"https://www.jax.org/strain/search?query=TNFRSF1A"},"sequence":{"accession":"P19438","fasta_url":"https://rest.uniprot.org/uniprotkb/P19438.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P19438/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P19438"}},"corpus_meta":[{"pmid":"19525953","id":"PMC_19525953","title":"Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci.","date":"2009","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19525953","citation_count":641,"is_preprint":false},{"pmid":"18535784","id":"PMC_18535784","title":"TLR-4, IL-1R and TNF-R signaling to NF-kappaB: variations on a common theme.","date":"2008","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/18535784","citation_count":373,"is_preprint":false},{"pmid":"9435233","id":"PMC_9435233","title":"The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor.","date":"1998","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9435233","citation_count":360,"is_preprint":false},{"pmid":"1698610","id":"PMC_1698610","title":"Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor.","date":"1990","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/1698610","citation_count":347,"is_preprint":false},{"pmid":"11443543","id":"PMC_11443543","title":"The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers.","date":"2001","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11443543","citation_count":252,"is_preprint":false},{"pmid":"10899034","id":"PMC_10899034","title":"TNFRSF1A mutations and autoinflammatory syndromes.","date":"2000","source":"Current opinion in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10899034","citation_count":191,"is_preprint":false},{"pmid":"9427646","id":"PMC_9427646","title":"Dominant-negative FADD inhibits TNFR60-, Fas/Apo1- and TRAIL-R/Apo2-mediated cell death but not gene induction.","date":"1998","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/9427646","citation_count":142,"is_preprint":false},{"pmid":"9743381","id":"PMC_9743381","title":"TNFR80-dependent enhancement of TNFR60-induced cell death is mediated by TNFR-associated factor 2 and is specific for TNFR60.","date":"1998","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9743381","citation_count":114,"is_preprint":false},{"pmid":"16508982","id":"PMC_16508982","title":"Neutrophils from patients with TNFRSF1A mutations display resistance to tumor necrosis factor-induced apoptosis: pathogenetic and clinical implications.","date":"2006","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/16508982","citation_count":114,"is_preprint":false},{"pmid":"24971461","id":"PMC_24971461","title":"Polymorphisms in the inflammatory pathway genes TLR2, TLR4, TLR9, LY96, NFKBIA, NFKB1, TNFA, TNFRSF1A, IL6R, IL10, IL23R, PTPN22, and PPARG are associated with susceptibility of inflammatory bowel disease in a Danish cohort.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24971461","citation_count":105,"is_preprint":false},{"pmid":"17785824","id":"PMC_17785824","title":"Bruton's tyrosine kinase mediates NF-kappa B activation and B cell survival by B cell-activating factor receptor of the TNF-R family.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17785824","citation_count":100,"is_preprint":false},{"pmid":"21068102","id":"PMC_21068102","title":"Association of STAT3 and TNFRSF1A with ankylosing spondylitis in Han Chinese.","date":"2010","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/21068102","citation_count":97,"is_preprint":false},{"pmid":"16287931","id":"PMC_16287931","title":"Systemic cytokine levels and the effects of etanercept in TNF receptor-associated periodic syndrome (TRAPS) involving a C33Y mutation in TNFRSF1A.","date":"2005","source":"Rheumatology (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/16287931","citation_count":78,"is_preprint":false},{"pmid":"11937569","id":"PMC_11937569","title":"Restricted localization of the TNF receptor CD120a to lipid rafts: a novel role for the death domain.","date":"2002","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11937569","citation_count":74,"is_preprint":false},{"pmid":"21225694","id":"PMC_21225694","title":"Long-term clinical profile of children with the low-penetrance R92Q mutation of the TNFRSF1A gene.","date":"2011","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/21225694","citation_count":73,"is_preprint":false},{"pmid":"10233758","id":"PMC_10233758","title":"Suppressed alloantigen presentation, increased TNF-alpha, IL-1, IL-1Ra, IL-10, and modulation of TNF-R in UV-irradiated human skin.","date":"1999","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/10233758","citation_count":71,"is_preprint":false},{"pmid":"18338763","id":"PMC_18338763","title":"Association of IL23R, TNFRSF1A, and HLA-DRB1*0103 allele variants with inflammatory bowel disease phenotypes in the Finnish population.","date":"2008","source":"Inflammatory bowel diseases","url":"https://pubmed.ncbi.nlm.nih.gov/18338763","citation_count":64,"is_preprint":false},{"pmid":"22111980","id":"PMC_22111980","title":"Pharmacogenetic analysis of TNF, TNFRSF1A, and TNFRSF1B gene polymorphisms and prediction of response to anti-TNF therapy in psoriasis patients in the Greek population.","date":"2012","source":"Molecular diagnosis & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/22111980","citation_count":63,"is_preprint":false},{"pmid":"24393624","id":"PMC_24393624","title":"The expanding spectrum of low-penetrance TNFRSF1A gene variants in adults presenting with recurrent inflammatory attacks: clinical manifestations and long-term follow-up.","date":"2013","source":"Seminars in arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/24393624","citation_count":63,"is_preprint":false},{"pmid":"29621649","id":"PMC_29621649","title":"The STAT3 Target Gene TNFRSF1A Modulates the NF-κB Pathway in Breast Cancer Cells.","date":"2018","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/29621649","citation_count":60,"is_preprint":false},{"pmid":"8996244","id":"PMC_8996244","title":"Membrane tumor necrosis factor (TNF) induced cooperative signaling of TNFR60 and TNFR80 favors induction of cell death rather than virus production in HIV-infected T cells.","date":"1997","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/8996244","citation_count":60,"is_preprint":false},{"pmid":"15692984","id":"PMC_15692984","title":"Association of the R92Q TNFRSF1A mutation and extracranial deep vein thrombosis in patients with Behçet's disease.","date":"2005","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/15692984","citation_count":58,"is_preprint":false},{"pmid":"7544644","id":"PMC_7544644","title":"Both tumor necrosis factor receptors, TNFR60 and TNFR80, are involved in signaling endothelial tissue factor expression by juxtacrine tumor necrosis factor alpha.","date":"1995","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/7544644","citation_count":57,"is_preprint":false},{"pmid":"10551865","id":"PMC_10551865","title":"Phosphorylation of tumor necrosis factor receptor CD120a (p55) by p42(mapk/erk2) induces changes in its subcellular localization.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10551865","citation_count":54,"is_preprint":false},{"pmid":"12452839","id":"PMC_12452839","title":"Hyper IgD syndrome (HIDS) associated with in vitro evidence of defective monocyte TNFRSF1A shedding and partial response to TNF receptor blockade with etanercept.","date":"2002","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12452839","citation_count":52,"is_preprint":false},{"pmid":"8089485","id":"PMC_8089485","title":"TNF receptor signal transduction. Ligand-dependent stimulation of a serine protein kinase activity associated with (CD120a) TNFR60.","date":"1994","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/8089485","citation_count":49,"is_preprint":false},{"pmid":"18180277","id":"PMC_18180277","title":"Clinical and functional characterisation of a novel TNFRSF1A c.605T>A/V173D cleavage site mutation associated with tumour necrosis factor receptor-associated periodic fever syndrome (TRAPS), cardiovascular complications and excellent response to etanercept treatment.","date":"2008","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/18180277","citation_count":49,"is_preprint":false},{"pmid":"26992170","id":"PMC_26992170","title":"Brief Report: Association of Tumor Necrosis Factor Receptor-Associated Periodic Syndrome With Gonosomal Mosaicism of a Novel 24-Nucleotide TNFRSF1A Deletion.","date":"2016","source":"Arthritis & rheumatology (Hoboken, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/26992170","citation_count":47,"is_preprint":false},{"pmid":"23039818","id":"PMC_23039818","title":"Differential expression of TNFR1 (CD120a) and TNFR2 (CD120b) on subpopulations of human monocytes.","date":"2012","source":"Journal of inflammation (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/23039818","citation_count":46,"is_preprint":false},{"pmid":"16463024","id":"PMC_16463024","title":"The TNFalpha receptor TNFRSF1A and genes encoding the amiloride-sensitive sodium channel ENaC as modulators in cystic fibrosis.","date":"2006","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16463024","citation_count":45,"is_preprint":false},{"pmid":"17665448","id":"PMC_17665448","title":"Late-onset tumor necrosis factor receptor-associated periodic syndrome in multiple sclerosis patients carrying the TNFRSF1A R92Q mutation.","date":"2007","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/17665448","citation_count":45,"is_preprint":false},{"pmid":"8690912","id":"PMC_8690912","title":"Protection against lethal Escherichia coli bacteremia in baboons (Papio anubis) by pretreatment with a 55-kDa TNF receptor (CD120a)-Ig fusion protein, Ro 45-2081.","date":"1996","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/8690912","citation_count":44,"is_preprint":false},{"pmid":"19541728","id":"PMC_19541728","title":"Incidence of TNFRSF1A mutations in German children: epidemiological, clinical and genetic characteristics.","date":"2009","source":"Rheumatology (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/19541728","citation_count":43,"is_preprint":false},{"pmid":"8218932","id":"PMC_8218932","title":"Differential regulation of tumour necrosis factor receptors (TNF-R) by IL-4; upregulation of P55 and P75 TNF-R on synovial joint mononuclear cells.","date":"1993","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/8218932","citation_count":42,"is_preprint":false},{"pmid":"11439381","id":"PMC_11439381","title":"Regenerating soleus and extensor digitorum longus muscles of the rat show elevated levels of TNF-alpha and its receptors, TNFR-60 and TNFR-80.","date":"2001","source":"Muscle & nerve","url":"https://pubmed.ncbi.nlm.nih.gov/11439381","citation_count":41,"is_preprint":false},{"pmid":"7636214","id":"PMC_7636214","title":"Activation of p42mapk/erk2 following engagement of tumor necrosis factor receptor CD120a (p55) in mouse macrophages.","date":"1995","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/7636214","citation_count":39,"is_preprint":false},{"pmid":"22059991","id":"PMC_22059991","title":"Role of tumour necrosis factor (TNF)-α and TNFRSF1A R92Q mutation in the pathogenesis of TNF receptor-associated periodic syndrome and multiple sclerosis.","date":"2011","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22059991","citation_count":39,"is_preprint":false},{"pmid":"23028454","id":"PMC_23028454","title":"Gene network revealed involvements of Birc2, Birc3 and Tnfrsf1a in anti-apoptosis of injured peripheral nerves.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23028454","citation_count":38,"is_preprint":false},{"pmid":"7515338","id":"PMC_7515338","title":"Soluble intercellular adhesion molecule-1 (ICAM-1), endothelial leukocyte adhesion molecule-1 (ELAM-1), and tumor necrosis factor receptor (55 kDa TNF-R) in patients with acute Plasmodium falciparum malaria.","date":"1994","source":"Clinical immunology and immunopathology","url":"https://pubmed.ncbi.nlm.nih.gov/7515338","citation_count":38,"is_preprint":false},{"pmid":"15280569","id":"PMC_15280569","title":"A novel mutation (T61I) in the gene encoding tumour necrosis factor receptor superfamily 1A (TNFRSF1A) in a Japanese patient with tumour necrosis factor receptor-associated periodic syndrome (TRAPS) associated with systemic lupus erythematosus.","date":"2004","source":"Rheumatology (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/15280569","citation_count":37,"is_preprint":false},{"pmid":"11175303","id":"PMC_11175303","title":"Tumor necrosis factor receptor-associated periodic syndrome (TRAPS) in a Dutch family: evidence for a TNFRSF1A mutation with reduced penetrance.","date":"2001","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/11175303","citation_count":36,"is_preprint":false},{"pmid":"25888769","id":"PMC_25888769","title":"The novel S59P mutation in the TNFRSF1A gene identified in an adult onset TNF receptor associated periodic syndrome (TRAPS) constitutively activates NF-κB pathway.","date":"2015","source":"Arthritis research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/25888769","citation_count":36,"is_preprint":false},{"pmid":"25010932","id":"PMC_25010932","title":"Association of TNF-α, TNFRSF1A and TNFRSF1B gene polymorphisms with the risk of sporadic breast cancer in northeast Chinese Han women.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25010932","citation_count":35,"is_preprint":false},{"pmid":"26245758","id":"PMC_26245758","title":"Deletion of angiotensin-converting enzyme 2 exacerbates renal inflammation and injury in apolipoprotein E-deficient mice through modulation of the nephrin and TNF-alpha-TNFRSF1A signaling.","date":"2015","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26245758","citation_count":35,"is_preprint":false},{"pmid":"15188372","id":"PMC_15188372","title":"Molecular analysis of the MVK and TNFRSF1A genes in patients with a clinical presentation typical of the hyperimmunoglobulinemia D with periodic fever syndrome: a low-penetrance TNFRSF1A variant in a heterozygous MVK carrier possibly influences the phenotype of hyperimmunoglobulinemia D with periodic fever syndrome or vice versa.","date":"2004","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/15188372","citation_count":35,"is_preprint":false},{"pmid":"9817170","id":"PMC_9817170","title":"Expression of three members of the TNF-R family of receptors (4-1BB, lymphotoxin-beta receptor, and Fas) in human lung.","date":"1998","source":"The European respiratory journal","url":"https://pubmed.ncbi.nlm.nih.gov/9817170","citation_count":35,"is_preprint":false},{"pmid":"16831294","id":"PMC_16831294","title":"Leukocyte infiltration and mRNA expression of IL-20, IL-8 and TNF-R P60 in psoriatic skin is driven by TNF-alpha.","date":"2006","source":"International journal of immunopathology and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/16831294","citation_count":34,"is_preprint":false},{"pmid":"19029521","id":"PMC_19029521","title":"Multiple sclerosis and the TNFRSF1A R92Q mutation: clinical characteristics of 21 cases.","date":"2008","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/19029521","citation_count":33,"is_preprint":false},{"pmid":"9712914","id":"PMC_9712914","title":"Cooperative signaling by tumor necrosis factor receptors CD120a (p55) and CD120b (p75) in the expression of nitric oxide and inducible nitric oxide synthase by mouse macrophages.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9712914","citation_count":32,"is_preprint":false},{"pmid":"20497537","id":"PMC_20497537","title":"Dynamic cross-talk analysis among TNF-R, TLR-4 and IL-1R signalings in TNFalpha-induced inflammatory responses.","date":"2010","source":"BMC medical genomics","url":"https://pubmed.ncbi.nlm.nih.gov/20497537","citation_count":31,"is_preprint":false},{"pmid":"18408954","id":"PMC_18408954","title":"TNF receptor-associated periodic syndrome (TRAPS): description of a novel TNFRSF1A mutation and response to etanercept.","date":"2008","source":"European journal of pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/18408954","citation_count":31,"is_preprint":false},{"pmid":"20430450","id":"PMC_20430450","title":"Validation of the CD6 and TNFRSF1A loci as risk factors for multiple sclerosis in Spain.","date":"2010","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/20430450","citation_count":31,"is_preprint":false},{"pmid":"24174586","id":"PMC_24174586","title":"Clinical relevance and functional consequences of the TNFRSF1A multiple sclerosis locus.","date":"2013","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/24174586","citation_count":30,"is_preprint":false},{"pmid":"18086728","id":"PMC_18086728","title":"A novel TNFRSF1A splice mutation associated with increased nuclear factor kappaB (NF-kappaB) transcription factor activation in patients with tumour necrosis factor receptor associated periodic syndrome (TRAPS).","date":"2007","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/18086728","citation_count":30,"is_preprint":false},{"pmid":"28396659","id":"PMC_28396659","title":"Disease Phenotype and Outcome Depending on the Age at Disease Onset in Patients Carrying the R92Q Low-Penetrance Variant in TNFRSF1A Gene.","date":"2017","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28396659","citation_count":30,"is_preprint":false},{"pmid":"15586174","id":"PMC_15586174","title":"Unexpected high frequency of P46L TNFRSF1A allele in sub-Saharan West African populations.","date":"2005","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/15586174","citation_count":30,"is_preprint":false},{"pmid":"11722598","id":"PMC_11722598","title":"Periodic fever (TRAPS) caused by mutations in the TNFalpha receptor 1 (TNFRSF1A) gene of three German patients.","date":"2001","source":"European journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/11722598","citation_count":30,"is_preprint":false},{"pmid":"7621589","id":"PMC_7621589","title":"Neutrophil expression of tumour necrosis factor receptors (TNF-R) and of activation markers (CD11b, CD43, CD63) in rheumatoid arthritis.","date":"1995","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7621589","citation_count":29,"is_preprint":false},{"pmid":"11817598","id":"PMC_11817598","title":"An Israeli Arab patient with a de novo TNFRSF1A mutation causing tumor necrosis factor receptor-associated periodic syndrome.","date":"2002","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/11817598","citation_count":29,"is_preprint":false},{"pmid":"15570662","id":"PMC_15570662","title":"Two familial cases with tumor necrosis factor receptor-associated periodic syndrome caused by a non-cysteine mutation (T50M) in the TNFRSF1A gene associated with severe multiorganic amyloidosis.","date":"2004","source":"The Journal of rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/15570662","citation_count":29,"is_preprint":false},{"pmid":"22994200","id":"PMC_22994200","title":"Associations of CD6, TNFRSF1A and IRF8 polymorphisms with risk of inflammatory demyelinating diseases.","date":"2013","source":"Neuropathology and applied neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/22994200","citation_count":28,"is_preprint":false},{"pmid":"30815272","id":"PMC_30815272","title":"Genetic polymorphisms in tumour necrosis factor receptors (TNFRSF1A/1B) illustrate differential treatment response to TNFα inhibitors in patients with Crohn's disease.","date":"2019","source":"BMJ open gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/30815272","citation_count":28,"is_preprint":false},{"pmid":"12105243","id":"PMC_12105243","title":"Mutational spectrum in the MEFV and TNFRSF1A genes in patients suffering from AA amyloidosis and recurrent inflammatory attacks.","date":"2002","source":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","url":"https://pubmed.ncbi.nlm.nih.gov/12105243","citation_count":27,"is_preprint":false},{"pmid":"31352465","id":"PMC_31352465","title":"Cerebellar Fastigial Nucleus Stimulation in a Chronic Unpredictable Mild Stress Rat Model Reduces Post-Stroke Depression by Suppressing Brain Inflammation via the microRNA-29c/TNFRSF1A Signaling Pathway.","date":"2019","source":"Medical science monitor : international medical journal of experimental and clinical research","url":"https://pubmed.ncbi.nlm.nih.gov/31352465","citation_count":27,"is_preprint":false},{"pmid":"11278725","id":"PMC_11278725","title":"Phosphorylation of the tumor necrosis factor receptor CD120a (p55) recruits Bcl-2 and protects against apoptosis.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11278725","citation_count":25,"is_preprint":false},{"pmid":"16308343","id":"PMC_16308343","title":"\"Periodic fever\" without fever: two cases of non-febrile TRAPS with mutations in the TNFRSF1A gene presenting with episodes of inflammation or monosymptomatic amyloidosis.","date":"2005","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/16308343","citation_count":25,"is_preprint":false},{"pmid":"10702263","id":"PMC_10702263","title":"Phosphorylation of the membrane proximal region of tumor necrosis factor receptor CD120a (p55) at ERK consensus sites.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10702263","citation_count":24,"is_preprint":false},{"pmid":"26621834","id":"PMC_26621834","title":"Genome-wide haplotype association study identify TNFRSF1A, CASP7, LRP1B, CDH1 and TG genes associated with Alzheimer's disease in Caribbean Hispanic individuals.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26621834","citation_count":24,"is_preprint":false},{"pmid":"14610673","id":"PMC_14610673","title":"Tumour necrosis factor receptor-associated periodic syndrome with a novel mutation in the TNFRSF1A gene in a Japanese family.","date":"2003","source":"European journal of pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/14610673","citation_count":24,"is_preprint":false},{"pmid":"23624563","id":"PMC_23624563","title":"TNFRSF1A polymorphisms rs1800693 and rs4149584 in patients with multiple sclerosis.","date":"2013","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/23624563","citation_count":23,"is_preprint":false},{"pmid":"19716548","id":"PMC_19716548","title":"Activation of the extrinsic apoptotic pathway by TNF-alpha in human salivary gland (HSG) cells in vitro, suggests a role for the TNF receptor (TNF-R) and intercellular adhesion molecule-1 (ICAM-1) in Sjögren's syndrome-associated autoimmune sialadenitis.","date":"2009","source":"Archives of oral biology","url":"https://pubmed.ncbi.nlm.nih.gov/19716548","citation_count":23,"is_preprint":false},{"pmid":"8625527","id":"PMC_8625527","title":"Elevation of plasma-soluble tumour necrosis factor receptors (TNF-R) in sarcoidosis.","date":"1996","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/8625527","citation_count":23,"is_preprint":false},{"pmid":"27239114","id":"PMC_27239114","title":"miR-29a up-regulation in AR42J cells contributes to apoptosis via targeting TNFRSF1A gene.","date":"2016","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/27239114","citation_count":20,"is_preprint":false},{"pmid":"15492850","id":"PMC_15492850","title":"Novel mutations in TNFRSF1A in patients with typical tumor necrosis factor receptor-associated periodic syndrome and with systemic lupus erythematosus in Japanese.","date":"2004","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/15492850","citation_count":20,"is_preprint":false},{"pmid":"32432099","id":"PMC_32432099","title":"Investigating the Causal Effect of Brain Expression of CCL2, NFKB1, MAPK14, TNFRSF1A, CXCL10 Genes on Multiple Sclerosis: A Two-Sample Mendelian Randomization Approach.","date":"2020","source":"Frontiers in bioengineering and biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/32432099","citation_count":20,"is_preprint":false},{"pmid":"25684197","id":"PMC_25684197","title":"Association of TNFAIP3 and TNFRSF1A variation with multiple sclerosis in a German case-control cohort.","date":"2015","source":"International journal of immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/25684197","citation_count":19,"is_preprint":false},{"pmid":"22272576","id":"PMC_22272576","title":"Evidence of genetic association between TNFRSF1A encoding the p55 tumour necrosis factor receptor, and ankylosing spondylitis in UK Caucasians.","date":"2012","source":"Clinical and experimental rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/22272576","citation_count":18,"is_preprint":false},{"pmid":"28401452","id":"PMC_28401452","title":"Polymorphism of Promoter Region of TNFRSF1A Gene (-610 T > G) as a Novel Predictive Factor for Radiotherapy Induced Oral Mucositis in HNC Patients.","date":"2017","source":"Pathology oncology research : POR","url":"https://pubmed.ncbi.nlm.nih.gov/28401452","citation_count":18,"is_preprint":false},{"pmid":"33066952","id":"PMC_33066952","title":"MiR-29a-3p Enhances the Viability of Rat Neuronal Cells that Injured by Oxygen-Glucose Deprivation/Reoxygenation Treatment Through Targeting TNFRSF1A and Regulating NF-κB Signaling Pathway.","date":"2020","source":"Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association","url":"https://pubmed.ncbi.nlm.nih.gov/33066952","citation_count":17,"is_preprint":false},{"pmid":"16401480","id":"PMC_16401480","title":"Severe TNF receptor-associated periodic syndrome due to 2 TNFRSF1A mutations including a new F60V substitution.","date":"2006","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/16401480","citation_count":17,"is_preprint":false},{"pmid":"29467762","id":"PMC_29467762","title":"Inositol-Requiring Enzyme 1-Mediated Downregulation of MicroRNA (miR)-146a and miR-155 in Primary Dermal Fibroblasts across Three TNFRSF1A Mutations Results in Hyperresponsiveness to Lipopolysaccharide.","date":"2018","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29467762","citation_count":17,"is_preprint":false},{"pmid":"20506103","id":"PMC_20506103","title":"Role of the R92Q TNFRSF1A mutation in patients with familial Mediterranean fever.","date":"2010","source":"Arthritis care & research","url":"https://pubmed.ncbi.nlm.nih.gov/20506103","citation_count":17,"is_preprint":false},{"pmid":"32964047","id":"PMC_32964047","title":"Overexpression of miR-29a-3p Suppresses Proliferation, Migration, and Invasion of Vascular Smooth Muscle Cells in Atherosclerosis via Targeting TNFRSF1A.","date":"2020","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/32964047","citation_count":17,"is_preprint":false},{"pmid":"11058695","id":"PMC_11058695","title":"Soluble receptors for tumor necrosis factor-alpha (TNF-R p55 and TNF-R p75) in familial combined hyperlipidemia.","date":"2000","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/11058695","citation_count":17,"is_preprint":false},{"pmid":"26278305","id":"PMC_26278305","title":"A Case Presenting with the Clinical Characteristics of Tumor Necrosis Factor (TNF) Receptor-associated Periodic Syndrome (TRAPS) without TNFRSF1A Mutations Successfully Treated with Tocilizumab.","date":"2015","source":"Internal medicine (Tokyo, Japan)","url":"https://pubmed.ncbi.nlm.nih.gov/26278305","citation_count":17,"is_preprint":false},{"pmid":"12832748","id":"PMC_12832748","title":"TNFRSF1A-associated periodic syndrome (TRAPS), Muckle-Wells syndrome (MWS) and renal amyloidosis.","date":"2003","source":"Journal of nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/12832748","citation_count":16,"is_preprint":false},{"pmid":"23745996","id":"PMC_23745996","title":"Expanding spectrum of TNFRSF1A gene mutations among patients with idiopathic recurrent acute pericarditis.","date":"2013","source":"Internal medicine journal","url":"https://pubmed.ncbi.nlm.nih.gov/23745996","citation_count":16,"is_preprint":false},{"pmid":"27990755","id":"PMC_27990755","title":"Efficacy of anakinra in an adult patient with recurrent pericarditis and cardiac tamponade as initial manifestations of tumor necrosis factor receptor-associated periodic syndrome due to the R92Q TNFRSF1A variant.","date":"2016","source":"International journal of rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/27990755","citation_count":16,"is_preprint":false},{"pmid":"7821811","id":"PMC_7821811","title":"Cloning, sequencing and partial functional characterization of the 5' region of the human p75 tumor necrosis factor receptor-encoding gene (TNF-R).","date":"1994","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/7821811","citation_count":16,"is_preprint":false},{"pmid":"27332769","id":"PMC_27332769","title":"Clinical and Genetic Features of Patients With TNFRSF1A Variants in Japan: Findings of a Nationwide Survey.","date":"2016","source":"Arthritis & rheumatology (Hoboken, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/27332769","citation_count":15,"is_preprint":false},{"pmid":"15657603","id":"PMC_15657603","title":"Identification of a novel mevalonate kinase gene mutation in combination with the common MVK V377I substitution and the low-penetrance TNFRSF1A R92Q mutation.","date":"2005","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/15657603","citation_count":15,"is_preprint":false},{"pmid":"23269568","id":"PMC_23269568","title":"The association of TNFRSF1A gene and MEFV gene mutations with adult onset Still's disease.","date":"2012","source":"Rheumatology international","url":"https://pubmed.ncbi.nlm.nih.gov/23269568","citation_count":14,"is_preprint":false},{"pmid":"31261789","id":"PMC_31261789","title":"TNF-α/TNF-R System May Represent a Crucial Mediator of Proliferative Synovitis in Hemophilia A.","date":"2019","source":"Journal of clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31261789","citation_count":14,"is_preprint":false},{"pmid":"19794511","id":"PMC_19794511","title":"Multiple sclerosis. TNFRSF1A, TRAPS and multiple sclerosis.","date":"2009","source":"Nature reviews. Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/19794511","citation_count":14,"is_preprint":false},{"pmid":"21459945","id":"PMC_21459945","title":"Candidate genes in patients with autoinflammatory syndrome resembling tumor necrosis factor receptor-associated periodic syndrome without mutations in the TNFRSF1A gene.","date":"2011","source":"The Journal of rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/21459945","citation_count":13,"is_preprint":false},{"pmid":"17949559","id":"PMC_17949559","title":"Overlap syndrome between FMF and TRAPS in a patient carrying MEFV and TNFRSF1A mutations.","date":"2007","source":"Clinical and experimental rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/17949559","citation_count":13,"is_preprint":false},{"pmid":"32563262","id":"PMC_32563262","title":"Neurological phenotypes in patients with NLRP3-, MEFV-, and TNFRSF1A low-penetrance variants.","date":"2020","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/32563262","citation_count":12,"is_preprint":false},{"pmid":"26598380","id":"PMC_26598380","title":"Differential impact of high and low penetrance TNFRSF1A gene mutations on conventional and regulatory CD4+ T cell functions in TNFR1-associated periodic syndrome.","date":"2015","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/26598380","citation_count":12,"is_preprint":false},{"pmid":"21565411","id":"PMC_21565411","title":"TNFRSF1A coding variants in multiple sclerosis.","date":"2011","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/21565411","citation_count":12,"is_preprint":false},{"pmid":"29148404","id":"PMC_29148404","title":"Other autoinflammatory disease genes in an FMF-prevalent population: a homozygous MVK mutation and a novel heterozygous TNFRSF1A mutation in two different Turkish families with clinical FMF.","date":"2017","source":"Clinical and experimental rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/29148404","citation_count":12,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":57291,"output_tokens":5696,"usd":0.128657,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":14088,"output_tokens":5716,"usd":0.10667,"stage2_stop_reason":"end_turn"},"total_usd":0.235327,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1998,\n      \"finding\": \"TNFRSF1A (TNF-R1/CD120a/TNFR60) is the high-affinity receptor for soluble TNF, with a Kd of ~19 pM at 37°C, approximately 20-fold higher affinity than TNFR2 (Kd ~420 pM). The high affinity is primarily due to the marked stability of the TNF–TNFR1 complex, explaining the predominant role of TNFR1 in cellular responses to soluble TNF.\",\n      \"method\": \"Binding kinetics (association and dissociation rate constants) measured at 37°C for both TNF receptors\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct in vitro binding assay with quantitative kinetic measurements, mechanistically explains receptor selectivity\",\n      \"pmids\": [\"9435233\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"The extracellular domain of TNFRSF1A contains four cysteine-rich repeats homologous to NGF receptor and CDw40. The receptor lacks intrinsic protein kinase activity yet can signal phosphorylation of specific cellular proteins. Soluble forms of the receptor are structurally identical to the extracellular cytokine-binding domain and are derived from the same transcripts encoding the cell-surface receptor.\",\n      \"method\": \"cDNA cloning using NH2-terminal amino acid sequence of soluble TBPI; transfection of CHO cells; immunological characterization with monoclonal antibodies\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — cDNA cloning with functional validation, amino acid sequence analysis, transfection experiments; foundational structural characterization\",\n      \"pmids\": [\"1698610\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"TNF binding to TNFRSF1A (TNFR60/CD120a) induces rapid, ligand-concentration-dependent association of a serine protein kinase activity with TNFR60 immune complexes, along with several phosphoproteins. The TNFR60-associated kinase activity phosphorylates proteins of 125, 97, 85, and 60 kDa and is inhibited by staurosporine but not by PKA/PKC inhibitors. TNFR80 did not show similar kinase association.\",\n      \"method\": \"Immunoprecipitation of TNFR60 from 32P-labeled U-937 cells; in vitro kinase assay on immune complexes; pharmacological inhibition\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal immunoprecipitation with in vitro kinase assay, single lab, well-controlled\",\n      \"pmids\": [\"8089485\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Cross-linking of TNFRSF1A (CD120a/p55) alone, but not CD120b (p75), is both necessary and sufficient for activation of p42mapk/erk2 in mouse macrophages, as determined using blocking and agonistic receptor-specific antibodies.\",\n      \"method\": \"Specific agonistic and blocking antibodies against each TNF receptor; p42mapk/erk2 activation measured by tyrosine phosphorylation in mouse macrophages\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — receptor-specific antibody approach with both blocking and agonistic reagents, single lab\",\n      \"pmids\": [\"7636214\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"FADD (dominant-negative mutant) is part of the TNFR60-initiated apoptotic pathway but does not play a role in TNFR60-mediated NF-κB or JNK gene induction. GFP-ΔFadd expression in HeLa cells inhibited TNFR60-, Fas/Apo1- and TRAIL-R/Apo2-mediated cell death without affecting TNF-mediated NF-κB or JNK activation.\",\n      \"method\": \"Stable expression of GFP-tagged dominant-negative FADD in HeLa cells; NF-κB and JNK activation assays; apoptosis assays\",\n      \"journal\": \"Current biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — dominant-negative genetic approach with multiple signaling readouts, dissecting apoptotic from gene-inductive signaling downstream of TNFR60\",\n      \"pmids\": [\"9427646\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"TNFR-associated factor 2 (TRAF2) is critically involved in both negative and positive regulation of TNFR60-induced cell death. TNFR80 costimulation enhances TNFR60-induced cell death selectively (not Fas/TRAIL/ceramide/daunorubicin-mediated death) through TNFR80-mediated depletion of antiapoptotic TRAF2 function. Overexpression of TRAF2 desensitized TNFR60-induced cell death, while a TRAF2 NF-κB-activation-deficient mutant enhanced it.\",\n      \"method\": \"Overexpression of wild-type and mutant TRAF2 in HeLa cells; receptor-specific antibody costimulation; JNK activation assays; cell death assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple mutant constructs with orthogonal functional readouts (cell death, JNK activation, NF-κB), mechanistic epistasis established\",\n      \"pmids\": [\"9743381\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Cross-linking of TNFRSF1A (CD120a/p55) is necessary and sufficient to induce iNOS mRNA expression and NO2- production in mouse macrophages, while CD120b (p75) augments this response by ligand-passing to CD120a and by initiating a separate sustained signaling event. Simultaneous ligation of both receptors leads to markedly prolonged iNOS mRNA/protein expression and potentiated nitric oxide production.\",\n      \"method\": \"Receptor-specific antibody-mediated cross-linking; anti-receptor blocking antibodies; CD120a- and CD120b-deficient mice; iNOS mRNA, protein, and NO2- quantification\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — receptor-specific antibodies, knockout mice, and multiple molecular readouts in a single study\",\n      \"pmids\": [\"9712914\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"p42mapk/erk2 phosphorylates the cytoplasmic domain of TNFRSF1A (CD120a/p55) at multiple Ser/Thr residues. Phosphorylation was induced by TNFα, GM-CSF, M-CSF, and zymosan in macrophages and blocked by immunodepletion of p42mapk/erk2 or PD098059. As a consequence of phosphorylation, CD120a expression at the plasma membrane and Golgi apparatus is lost and the receptor accumulates in intracellular tubular structures associated with the endoplasmic reticulum. Mutation of the four ERK consensus phosphorylation sites to Ala prevented ER-tubular redistribution.\",\n      \"method\": \"GST-CD120a fusion protein as substrate for in vitro phosphorylation; 32P metabolic labeling; COS-7 cell transfection with CD120a and constitutively active MEK-1; site-directed mutagenesis; confocal microscopy\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro kinase assay, metabolic labeling, site-directed mutagenesis, and subcellular localization, multiple orthogonal methods\",\n      \"pmids\": [\"10551865\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"The preferred phosphorylation sites on TNFRSF1A (CD120a/p55) by p42mapk/erk2 are Thr-236 and Ser-270 within the membrane proximal region; primary phosphorylation at these sites enables subsequent phosphorylation at Ser-240 and Ser-244. CD120a (p55) itself is necessary and sufficient for induction of ERK kinase activity, as demonstrated using receptor-deficient mice.\",\n      \"method\": \"Deletional and site-directed mutagenesis of CD120a cytoplasmic domain; 32P phosphorylation mapping; mice deficient in CD120a, CD120b, or both\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — site-directed mutagenesis plus genetic knockout mice, identifying specific phosphorylation sites\",\n      \"pmids\": [\"10702263\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Phosphorylation of TNFRSF1A (CD120a) by p42mapk/erk2 inhibits the apoptotic activity of the receptor while preserving its ability to activate NF-κB. Phosphorylated CD120a is re-localized from the Golgi to tubular ER structures where it recruits Bcl-2. Antisense-mediated knockdown of Bcl-2 reversed the protection from apoptosis conferred by receptor phosphorylation.\",\n      \"method\": \"p42mapk/erk2 overexpression; antisense Bcl-2 knockdown; subcellular localization; apoptosis and NF-κB assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal approaches (kinase overexpression, antisense knockdown, localization, functional apoptosis/NF-κB assays) in single study\",\n      \"pmids\": [\"11278725\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"The death domain (DD) of TNFRSF1A (CD120a) is both necessary and sufficient to promote localization of the receptor to lipid rafts. Deletion of the DD, pairwise deletion of individual DD alpha-helices, or introduction of the lpr mutation (L351N) all prevented raft localization and abolished apoptotic signaling. CD120b (which lacks a DD) is absent from the Golgi but present in bulk plasma membrane; a chimeric receptor with the CD120a DD fused to CD120b cytoplasmic domain was predominantly localized to lipid rafts.\",\n      \"method\": \"Confocal microscopy; sucrose density gradient ultracentrifugation; deletion and point mutagenesis; chimeric receptor construction; apoptosis assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — mutagenesis combined with fractionation and imaging, directly linking DD-mediated raft localization to apoptotic signaling\",\n      \"pmids\": [\"11937569\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"One mechanism of autoinflammation in TRAPS is impaired cleavage/shedding of the TNFRSF1A ectodomain upon cellular activation in patients with certain mutations. Mutations in the extracellular cysteine-rich domains (especially those disrupting disulfide bonds) reduce shedding of the soluble antagonistic form of the receptor.\",\n      \"method\": \"Functional studies of TNFRSF1A shedding in patient cells; mutational analysis of extracellular domain\",\n      \"journal\": \"Current opinion in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — functional shedding assays in patient-derived cells, replicated across multiple TRAPS patient studies\",\n      \"pmids\": [\"10899034\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"A novel splice-site mutation in TNFRSF1A (c.472+1G>A) causes a 45-nucleotide insertion of intronic DNA resulting in an in-frame insertion of 15 amino acids and deletion of Cys129 in CRD3 of the mature TNFR1 protein. This mutation reduces serum soluble TNFR1 levels, decreases surface TNFR1 expression, and increases basal NF-κB activation in PBMCs compared with healthy controls and other TRAPS mutations.\",\n      \"method\": \"Western blot; multiplex bead cytokine immunoassay; ELISA for sTNFR1; FACS for surface TNFR1; NF-κB ELISA-based transcription factor assay\",\n      \"journal\": \"Annals of the rheumatic diseases\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (protein expression, surface expression, signaling), single lab patient study\",\n      \"pmids\": [\"18086728\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"The novel S59P TNFRSF1A mutation causes cytoplasmic accumulation/defective trafficking of TNF-R1 and constitutively activates the NF-κB, IL-1β, MAPK, and SRC/JAK/STAT3 pathways and inhibits apoptosis. This mutation also leads to enhanced and persistent IL-6 and IL-8 secretion from PBMCs in response to IL-1β stimulation.\",\n      \"method\": \"HEK-293 cell transfection with mutant constructs; immunofluorescence; immunoblotting for p-IκBα and p65; cytokine array; PBMC stimulation assays\",\n      \"journal\": \"Arthritis research & therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — transfection-based functional study with multiple signaling readouts and patient PBMC validation, single lab\",\n      \"pmids\": [\"25888769\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"The MS susceptibility allele rs1800693(G) in the TNFRSF1A locus generates an RNA isoform, TNFRSF1A Δ6, lacking the transmembrane and cytoplasmic domains. This allele alters monocyte responses, causing a more robust transcriptional induction of CXCL10 and other genes in response to TNF-α, without detectably altering serum levels of soluble TNFRSF1A.\",\n      \"method\": \"Real-time PCR for isoform expression; ELISA for serum sTNFR1; transcriptional profiling of monocytes from genotyped donors; prospective clinical data analysis\",\n      \"journal\": \"Neurology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — isoform characterization and functional monocyte assays, single lab but multiple methods\",\n      \"pmids\": [\"24174586\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TNFRSF1A is a direct transcriptional target of STAT3 in breast cancer cells. STAT3 binds directly to a regulatory region within the TNFRSF1A gene, and TNFRSF1A levels depend on STAT3 function in both constitutive and cytokine-induced STAT3 activation models. TNFRSF1A is a major mediator of both basal and TNFα-induced NF-κB activity in triple-negative breast cancer cells.\",\n      \"method\": \"STAT3 inhibitor treatment + gene expression analysis; chromatin binding assay (STAT3 binding to TNFRSF1A regulatory region); siRNA knockdown of TNFRSF1A; NF-κB reporter assays\",\n      \"journal\": \"Neoplasia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct STAT3 binding to TNFRSF1A regulatory region plus functional knockdown with NF-κB readout, single lab, two orthogonal methods\",\n      \"pmids\": [\"29621649\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"In TRAPS patient-derived dermal fibroblasts carrying TNFRSF1A mutations, TNFR1 surface expression is absent/deficient. These cells fail to upregulate miR-146a and miR-155 in response to LPS, leading to hyperresponsive cytokine production. This failure is mechanistically dependent on IRE1 (inositol-requiring enzyme 1): IL-1β produced by unfolded protein response activation downregulates miR-146a and miR-155 in an IRE1-dependent manner, impairing NF-κB negative feedback.\",\n      \"method\": \"Immunofluorescence for TNFR1 surface expression; RT-qPCR for miRNA expression; IRE1 inhibitor (4u8C); ELISA for cytokines; microfluidics miRNA profiling\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — patient-derived fibroblasts with pharmacological inhibitor and multiple readouts, single lab\",\n      \"pmids\": [\"29467762\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Neutrophils from TRAPS patients with cysteine or threonine residue mutations (but not those with the R92Q substitution) display resistance to TNF-induced apoptosis and absent caspase-8 activation, in contrast to normal controls and R92Q carriers, suggesting that structural TNFRSF1A mutations impair TNFR1-mediated apoptotic signaling.\",\n      \"method\": \"Neutrophil stimulation with TNFα + cycloheximide; annexin V binding by flow cytometry; caspase-8 activation assay\",\n      \"journal\": \"Arthritis and rheumatism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional apoptosis and caspase assays in patient-derived primary cells, multiple mutation types compared, single lab\",\n      \"pmids\": [\"16508982\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"In HIV-infected T cells, TNFR60 (TNFRSF1A) dominantly signals HIV production upon selective stimulation, while simultaneous activation of both TNFR60 and TNFR80 by membrane TNF (but not soluble TNF) switches the cellular response from viral production to enhanced apoptosis, demonstrating cooperative/antagonistic signaling between the two TNF receptors.\",\n      \"method\": \"Receptor-specific agonistic and antagonistic antibodies; coculture with cells expressing noncleavable membrane TNF; HIV production measurement; apoptosis assays\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — receptor-specific antibodies and membrane-TNF coculture system with functional readouts, single lab\",\n      \"pmids\": [\"8996244\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"High-penetrance TNFRSF1A mutations cause hyperactivation of ERK1/2, STAT1/3/5, mTOR, and NF-κB signaling pathways in conventional CD4+ T cells, and reduce the frequency and suppressive function of peripheral regulatory T cells. Low-penetrance mutations show partial versions of these alterations.\",\n      \"method\": \"Phosphoflow cytometry for signaling pathways; frequency and functional assays of Treg and conventional T cells in TRAPS patient peripheral blood\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — patient-derived primary cells with multiple signaling readouts, single lab\",\n      \"pmids\": [\"26598380\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TNFRSF1A (TNFR1/CD120a/p55) is the high-affinity, death domain-containing receptor for soluble TNF that, upon ligand binding and clustering, recruits FADD and TRAF2 to activate both NF-κB (gene induction) and caspase-dependent apoptosis; its death domain is required for lipid raft localization and apoptotic signaling, while phosphorylation of its cytoplasmic domain by p42mapk/erk2 at Thr-236/Ser-270 redistributes the receptor to ER tubules where it recruits Bcl-2 to suppress apoptosis while preserving NF-κB signaling; soluble TNFRSF1A generated by ectodomain shedding acts as an antagonist, and disease-causing TRAPS mutations in the extracellular cysteine-rich domains impair shedding and receptor trafficking, leading to constitutive NF-κB and inflammasome pathway activation; additionally, TNFRSF1A is a direct STAT3 transcriptional target that mediates basal and TNFα-induced NF-κB activity in cancer cells.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"TNFRSF1A (TNFR1/CD120a/p55) is the high-affinity receptor for soluble TNF, binding with ~19 pM affinity owing to the marked stability of the TNF–TNFR1 complex, which explains its predominant role in cellular responses to soluble TNF relative to TNFR2 [#0]. Its extracellular region comprises four cysteine-rich repeats and, although the receptor lacks intrinsic kinase activity, ligand binding drives signaling through recruited effectors [#1]. Upon engagement, TNFR1 bifurcates into a death-inducing pathway dependent on FADD and a gene-inductive NF-κB/JNK pathway that proceeds independently of FADD [#4], with TRAF2 acting as a rheostat that both restrains and licenses TNFR1-induced cell death [#5]; cross-linking of TNFR1 alone is necessary and sufficient to activate p42mapk/erk2 and to induce iNOS expression in macrophages [#3, #6]. The receptor's death domain is both necessary and sufficient for partitioning into lipid rafts, a localization required for apoptotic signaling [#10]. TNFR1 signaling output is tuned by ERK-dependent phosphorylation: p42mapk/erk2 phosphorylates the cytoplasmic domain at Thr-236 and Ser-270 (priming further phosphorylation at Ser-240/Ser-244), redistributing the receptor from the Golgi/plasma membrane into ER-associated tubular structures where it recruits Bcl-2 to suppress apoptosis while preserving NF-κB activation [#7, #8, #9]. Mutations in the extracellular cysteine-rich domains cause TNF receptor-associated periodic syndrome (TRAPS) by impairing ectodomain shedding and receptor trafficking, producing surface-deficient, cytoplasmically retained receptor that constitutively drives NF-κB, IL-1β/MAPK, and STAT3 signaling, resists TNF-induced apoptosis, and disrupts NF-κB negative feedback [#11, #13, #16, #17]. TNFRSF1A is itself a direct STAT3 transcriptional target that mediates basal and TNFα-induced NF-κB activity in breast cancer cells [#15].\",\n  \"teleology\": [\n    {\n      \"year\": 1990,\n      \"claim\": \"Established the molecular identity of TNFR1 as a four-cysteine-rich-repeat surface receptor lacking intrinsic kinase activity, defining how it must signal through recruited partners and explaining the origin of soluble receptor.\",\n      \"evidence\": \"cDNA cloning from soluble TBPI sequence, CHO transfection, and monoclonal antibody characterization\",\n      \"pmids\": [\"1698610\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify the kinases or adaptors that mediate phosphorylation downstream\", \"Mechanism of soluble receptor generation not resolved\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Showed that TNF binding selectively recruits a serine kinase activity to TNFR1 (not TNFR2), beginning to explain how a kinase-deficient receptor transduces phosphorylation signals.\",\n      \"evidence\": \"Immunoprecipitation of TNFR60 from 32P-labeled U-937 cells with in vitro kinase assay and pharmacological inhibition\",\n      \"pmids\": [\"8089485\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Identity of the associated kinase not established\", \"Substrate proteins (125/97/85/60 kDa) not identified\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Demonstrated that TNFR1 cross-linking alone is necessary and sufficient to activate ERK2, attributing a specific MAPK output to this receptor.\",\n      \"evidence\": \"Receptor-specific agonistic/blocking antibodies and ERK2 tyrosine phosphorylation readout in mouse macrophages\",\n      \"pmids\": [\"7636214\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not map the route from receptor to ERK activation\", \"Single cell type\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Revealed receptor cross-talk: TNFR1 dominantly signals HIV production, but co-activation with TNFR2 by membrane TNF switches output toward apoptosis, showing ligand form dictates outcome.\",\n      \"evidence\": \"Receptor-specific antibodies and noncleavable membrane-TNF coculture in HIV-infected T cells\",\n      \"pmids\": [\"8996244\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular basis of the soluble-vs-membrane TNF switch not defined\", \"Single-lab system\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Separated TNFR1's two signaling arms genetically — FADD drives apoptosis but is dispensable for NF-κB/JNK — and identified TRAF2 as a bidirectional regulator of death, establishing the apoptosis-versus-gene-induction dichotomy.\",\n      \"evidence\": \"Dominant-negative FADD and wild-type/mutant TRAF2 overexpression in HeLa with cell death, NF-κB, and JNK readouts\",\n      \"pmids\": [\"9427646\", \"9743381\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of FADD vs TRAF2 recruitment not resolved\", \"How TRAF2 levels are set in vivo unclear\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Quantified TNFR1 as the high-affinity soluble-TNF receptor and attributed selectivity to complex stability, explaining why TNFR1 dominates responses to soluble ligand.\",\n      \"evidence\": \"Binding kinetics with association/dissociation rate constants at 37°C for both receptors\",\n      \"pmids\": [\"9435233\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not address membrane-TNF binding behavior\", \"No structural model of the stabilized complex\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Showed TNFR1 is necessary and sufficient to induce iNOS/NO in macrophages with TNFR2 augmenting via ligand-passing, mapping an inflammatory effector output to the receptor.\",\n      \"evidence\": \"Receptor-specific antibodies, knockout mice, and iNOS mRNA/protein/NO2- quantification\",\n      \"pmids\": [\"9712914\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Intracellular pathway linking TNFR1 to iNOS not fully traced\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Identified ERK2 as the kinase phosphorylating the TNFR1 cytoplasmic domain at multiple Ser/Thr sites, with phosphorylation driving relocation from plasma membrane/Golgi into ER tubules — linking covalent modification to receptor trafficking.\",\n      \"evidence\": \"GST-CD120a in vitro kinase assay, 32P labeling, site-directed mutagenesis, and confocal microscopy in COS-7 cells\",\n      \"pmids\": [\"10551865\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of ER relocation not yet shown\", \"Sequence/identity of phospho-sites not yet mapped at this stage\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Pinpointed Thr-236 and Ser-270 as primary ERK phosphorylation sites priming secondary Ser-240/Ser-244 phosphorylation, providing residue-level resolution of the trafficking switch.\",\n      \"evidence\": \"Deletional/site-directed mutagenesis, 32P phospho-mapping, and TNF-receptor-deficient mice\",\n      \"pmids\": [\"10702263\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The phosphatase reversing these modifications unknown\", \"Stoichiometry of phosphorylation in vivo unclear\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Established the functional output of ERK phosphorylation: relocated TNFR1 recruits Bcl-2 in ER tubules to block apoptosis while preserving NF-κB, defining a phosphorylation-controlled pro-survival switch.\",\n      \"evidence\": \"ERK2 overexpression, antisense Bcl-2 knockdown, localization, and apoptosis/NF-κB assays\",\n      \"pmids\": [\"11278725\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct TNFR1–Bcl-2 interaction interface not defined\", \"Generality across cell types not established\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Showed the death domain is necessary and sufficient for TNFR1 lipid-raft localization and that raft partitioning is required for apoptosis, tying a specific subdomain to a specific signaling compartment.\",\n      \"evidence\": \"Deletion/point mutagenesis (including lpr L351N), chimeric receptors, sucrose-gradient fractionation, confocal imaging, and apoptosis assays\",\n      \"pmids\": [\"11937569\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Raft components recruited by the DD not identified\", \"Relationship between raft and ER-tubule pools unresolved\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Demonstrated that structural (cysteine/threonine) TRAPS mutations, but not R92Q, impair TNFR1-mediated apoptosis with absent caspase-8 activation, linking specific mutation classes to defective death signaling.\",\n      \"evidence\": \"TNFα+cycloheximide stimulation of patient neutrophils with annexin V and caspase-8 assays\",\n      \"pmids\": [\"16508982\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism connecting structural mutation to caspase-8 failure not defined\", \"Small mutation-type cohort\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Proposed impaired ectodomain shedding as a TRAPS mechanism, where CRD mutations reduce production of the antagonistic soluble receptor.\",\n      \"evidence\": \"Functional shedding assays in patient cells with extracellular-domain mutational analysis\",\n      \"pmids\": [\"10899034\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Shedding defect does not explain all TRAPS mutations\", \"Quantitative contribution to disease unclear\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Linked a specific splice/CRD3 mutation to reduced soluble and surface TNFR1 with elevated basal NF-κB, refining the trafficking-defect model of TRAPS.\",\n      \"evidence\": \"Western blot, sTNFR1 ELISA, surface FACS, and NF-κB transcription-factor assay in patient PBMCs\",\n      \"pmids\": [\"18086728\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism connecting retention to constitutive NF-κB not established\", \"Single mutation\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Showed the MS-associated rs1800693(G) allele produces a soluble TNFRSF1A Δ6 isoform lacking transmembrane/cytoplasmic domains and enhances TNF-driven CXCL10 induction in monocytes, connecting a common variant to altered TNF responsiveness.\",\n      \"evidence\": \"Isoform RT-PCR, serum sTNFR1 ELISA, and monocyte transcriptional profiling in genotyped donors\",\n      \"pmids\": [\"24174586\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How the Δ6 isoform alters signaling mechanistically unclear\", \"No change in serum soluble receptor detected\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Demonstrated that an S59P TRAPS mutation causes cytoplasmic receptor retention and constitutive activation of NF-κB, IL-1β, MAPK, and SRC/JAK/STAT3 pathways with apoptosis resistance, broadening the multi-pathway hyperactivation model.\",\n      \"evidence\": \"HEK-293 transfection, immunofluorescence, immunoblotting, cytokine arrays, and patient PBMC stimulation\",\n      \"pmids\": [\"25888769\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism converting trafficking defect to constitutive multi-pathway activation undefined\", \"Single mutation\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Extended TRAPS signaling dysregulation to adaptive immunity, showing high-penetrance mutations hyperactivate ERK/STAT/mTOR/NF-κB in CD4+ T cells and impair regulatory T cells.\",\n      \"evidence\": \"Phosphoflow cytometry and Treg frequency/function assays in patient peripheral blood\",\n      \"pmids\": [\"26598380\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cell-intrinsic vs systemic causes of Treg defect not separated\", \"Penetrance-dependent mechanism not resolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Connected TRAPS receptor deficiency to failed miRNA-based NF-κB feedback via an IRE1/UPR–IL-1β axis, providing a mechanistic basis for cytokine hyperresponsiveness.\",\n      \"evidence\": \"Patient-derived fibroblasts, RT-qPCR for miR-146a/miR-155, IRE1 inhibitor 4u8C, and cytokine ELISA\",\n      \"pmids\": [\"29467762\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How TNFR1 deficiency triggers UPR not defined\", \"In vivo relevance to flares unclear\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identified TNFRSF1A as a direct STAT3 transcriptional target driving basal and TNFα-induced NF-κB in triple-negative breast cancer, placing the receptor downstream of an oncogenic transcription factor.\",\n      \"evidence\": \"STAT3 inhibition with expression analysis, STAT3 chromatin-binding assay, TNFRSF1A siRNA, and NF-κB reporter assays\",\n      \"pmids\": [\"29621649\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"STAT3-binding element not finely mapped\", \"In vivo tumor relevance not tested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the lipid-raft (death-inducing) and ER-tubule (Bcl-2-protective) receptor pools are dynamically partitioned, and how this balance is dysregulated by TRAPS mutations to drive constitutive inflammation, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking phospho-trafficking, raft localization, and TRAPS pathology\", \"Phosphatases and shedding proteases not characterized in the corpus\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 1, 4]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [9, 10]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [7, 10]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [7, 9]},\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [7, 10]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 4, 5]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [4, 9, 10, 17]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [6, 16, 19]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [11, 13, 16]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"TNF\", \"FADD\", \"TRAF2\", \"BCL2\", \"STAT3\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}